IP Library Granted Patent US 11,052,122
Granted Patent B2
US 11,052,122 · App. 16/155,502 · Granted Jul 6, 2021

Lactic bacteria and their use in the prevention of diarrhea

Inventor: Francois-Marie Luquet (Orsay, FR)
Assignee: Kerry Luxembourg S.à.r.l.
A61K35/747A23L33/135A23V2002/00A23Y2220/17A61K2035/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,052,122
App. No.
16/155,502
Granted
Jul 6, 2021
Kind
B2
Abstract

The present invention concerns a lactic composition useful for the prevention or treatment of diarrhea such as antibiotic associated diarrhea or “tourista.” The composition according to the invention contains at least a bacterial strain selected from the group consisting of Lactobacillus acidophilus, Lactobacillus acidophilus I-1492, Lactobacillus casei and a mixture of thereof.

Claims (28)

1. A method of preventing antibiotic associated diarrhea (AAD) comprising orally administering to a human adult receiving an antibiotic therapy a fermented food product consisting of a mixture of Lactobacilli and fermented proteins,

wherein the mixture of Lactobacilli comprises Lactobacillus acidophilus I-1492 strain deposited at the CNCM and a Lactobacillus casei strain, and

wherein said method prevents AAD by reducing at least one of incidence of antibiotic associated diarrhea (AAD), severity of AAD, or duration of AAD.

2. The method of claim 1 , wherein the fermented proteins comprise fermented soy proteins.

3. The method of claim 1 , wherein the fermented food product is a food supplement.

4. The method of claim 1 , wherein the fermented food product is administered as a gel or a capsule.

5. The method of claim 4 , wherein the gel or the capsule comprises at least 50 billion colony forming units (CFUs) of a population of living and active micro-organisms of the Lactobacillus acidophilus I-1492 strain.

6. The method of claim 4 , wherein the gel or the capsule comprises at least 100 billion colony forming units (CFUs) of a population of living and active micro-organisms of the Lactobacillus acidophilus I-1492 strain.

7. The method of claim 1 , wherein the antibiotic associated diarrhea is caused by a Clostridium difficile infection.

8. The method of claim 1 , wherein the mixture of Lactobacilli consists essentially of the Lactobacillus acidophilus I-1492 strain deposited at the CNCM and a Lactobacillus casei strain.

9. The method of claim 1 , wherein the mixture of Lactobacilli consists of the Lactobacillus acidophilus I-1492 strain deposited at the CNCM and a Lactobacillus casei strain.

10. The method of claim 1 , wherein said method reduces duration of hospitalization of the patient as compared to duration of another hospitalized patient receiving the same antibiotic therapy but not the fermented food product.

11. The method of claim 1 , wherein said method reduces presence of blood in stools of the subject compared to another subject receiving the same antibiotic therapy but not the fermented food product.

12. The method of claim 1 , wherein the method prevents AAD by reducing an average number of liquid stools in the subject compared to another subject receiving the same antibiotic therapy but not the fermented food product.

13. The method of claim 1 , wherein the composition is administered within 48 hours following beginning of antibiotic therapy or for a total duration of antibiotic therapy.

14. A method of preventing antibiotic associated diarrhea (AAD) comprising orally administering to a human adult receiving an antibiotic therapy a fermented food product consisting of a mixture of Lactobacilli and fermented proteins, wherein the mixture of Lactobacilli comprises Lactobacillus acidophilus I-1492 strain deposited at the CNCM and a Lactobacillus casei strain, and

wherein said fermented food product is administered within 48 hours following beginning of antibiotic therapy or for a total duration of antibiotic therapy.

15. The method of claim 14 , wherein the fermented proteins comprise fermented soy proteins.

16. The method of claim 14 , wherein the fermented food product is a food supplement.

17. The method of claim 14 , wherein the fermented food product is administered as a gel or a capsule.

18. The method of claim 17 , wherein the gel or the capsule comprises at least 50 billion colony forming units (CFUs) of a population of living and active micro-organisms of the Lactobacillus acidophilus I-1492 strain.

19. The method of claim 17 , wherein the gel or the capsule comprises at least 100 billion colony forming units (CFUs) of a population of living and active micro-organisms of the Lactobacillus acidophilus I-1492 strain.

20. The method of claim 14 , wherein the antibiotic associated diarrhea is caused by a Clostridium difficile infection.

21. The method of claim 14 , wherein the mixture of Lactobacilli consists essentially of the Lactobacillus acidophilus I-1492 strain deposited at the CNCM and a Lactobacillus casei strain.

22. The method of claim 14 , wherein the mixture of Lactobacilli consists of the Lactobacillus acidophilus I-1492 strain deposited at the CNCM and a Lactobacillus casei strain.

23. A method of preventing antibiotic associated diarrhea (AAD) comprising orally administering to a human adult receiving an antibiotic therapy a fermented food product consisting of a mixture of Lactobacilli and fermented proteins,

wherein the mixture of Lactobacilli comprises Lactobacillus acidophilus I-1492 strain deposited at the CNCM and a Lactobacillus casei strain, and

wherein said fermented food product is administered within 48 hours following beginning of antibiotic therapy or for a total duration of antibiotic therapy.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2022
From: KERRY LUXEMBOURG S.A.R.L.
To: KERRY GROUP SERVICES INTERNATIONAL LIMITED
Reel/Frame 058792/0891 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2020
From: BIO-K PLUS INTERNATIONAL INC.
To: KERRY LUXEMBOURG S.A.R.L.
Reel/Frame 054738/0524 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2018
From: LUQUET, FRANCOIS-MARIE
To: BIO-K PLUS INTERNATIONAL, INC.
Reel/Frame 047109/0922 →
Priority Claims (1)
CA CA 2470090 · Jun 18, 2004 · national
Continuity (4)
Division 15597613 · May 17, 2017
Continuation 13109287 · May 17, 2011
Division 11570752
Related Publication 20190038683A1 · Feb 7, 2019